When the Supreme Court made their decision on the Citizens United v. F.E.C. case in 2010, they changed our electoral landscape by opening the door for many special interests groups and billionaires to spend an untraceable, unlimited amount of money to tip the balance of power in their favor. Billionaires like the Koch Brothers are now not held accountable and can influence American politics in a completely legal, tremendous way.
The idea that “corporations are people” has not set well with many citizens. End Citizens United was created in 2015 as a Political Action Committee that was funded by their grassroots donors, with the dedication to counteract the Supreme Court’s ridiculous 2010 decision. End Citizens United plans on showing the country’s citizens, voters, candidates, and officials that the grassroots movement in this country will not back down and will fight against the boldness of billionaires and special interests.
End Citizens United plans on dismantling the big money that is being put into politics by pressuring lawmakers to take action and campaign a true finance reform. This PAC plans to elect campaign finance reform champions that will help citizens pass state and national ballot measures. The ultimate goal is to overturn the Citizens United v. F.E.C. decision. End Citizens United hopes to eventually end the unlimited money that is syphoned into the country’s political system. They will use their grassroots members to show their political power against money in politics, raise the issue of money as a larger priority, and elect pro-reform candidates.
Most champions of finance reform that are supported by End Citizens United are members of the Democratic Party. End Citizens United knows that most people in the country can agree that political spending is out of the control, including Republicans and Independents. Republican leadership in Congress however is part of what is standing directly in the way of overturning the decision. They stand up for their Democratic candidates to fight against special interest groups and mega-donors.
In less than 6 months, End Citizens United received over $2 million in donations, mostly from small donors and grassroots members. Over 300,000 people have signed their petition that demands the overturning of the Supreme Court’s decision, with that number likely in increase as its movement spreads. End Citizens United even partnered with “Ready for Hillary”, gaining access to their email list of over 4 million people to assist them in reaching more potential liberal supporters.
While there is always talk about campaign finance reform, End Citizens United has entered the hole in the conversation by addressing the political side of it. With plans to actually elect people, End Citizens United seems to be the first PAC to have significant influence by its millions of grassroots members.
Arthur Becker is a self-made individual. According to ideamensch.com, having been involved in many projects over the past, he has developed a highly innovative mind. Together with hard work, a man of great skill in real estate, biotechnology, and information technology has been created. He is a man who greatly believes in talent. A nation can only progress if only it invests both money and time on talented young and energetic minds.
As a young man, Arthur Becker mastered the art of being a successful entrepreneur. Having basic knowledge in business, he got to identify with what really drives an economy. In Arthur Becker’s view, being flexible is the key to success since it allows one to be highly adaptive to different clients and at different times.
Arthur Becker is not a man whose success was given on a silver platter. He had to toil like any other man so as to reach where he is today. At the age of sixteen, Arthur Becker was able to secure employment at the Parks Department, a job that hardly paid him much. With an undying passion to become better in life, he felt motivated to find himself an interesting but rather challenging job.
Being an entrepreneur, Arthur Becker has tried his hand in different businesses. However, not all of them have succeeded, but Arthur Becker has used his mistakes as a lesson in life. For the many companies that he has worked with, Arthur Becker has found that internal cohesion between both workers and top management is highly crucial. It is only a company which works as one cohesive unit that ends up succeeding.
In addition, Arthur Becker has a vested interest in cancer treatment. Other professions that interest him include information technology and real estate. He has in the past been able to work for companies like NaviSite in the capacity of CEO and senior advisor for Vera Wang Fashion Company. See, http://www.nytimes.com/1989/06/23/style/vera-wang-wed-to-arthur-becker.html.
Presently, Arthur Becker is both chairman and chief executive officer of Zinio LLC. He is also the managing member of Atlantic Investors LLC and the managing director of Madison Technology Group LLC.
JeanMarie Guenot is the president and CEO of Amphivena Therapeutics, a company that focuses on the development of innovative bi-functional antibody treatments for hematologic malignancies. She is highly knowledgeable in the pharmaceutical and biotechnology industries. In her 20 years of service, she worked for different companies ranging from public and private, corporate & commercial development, pharmaceutical R&D, venture capital and project & alliance management, to business development.
Jeanmarie’s website highlights how she is highly trained in physical and mechanical chemistry. She pursued legal studies at the University of California, San Francisco. The alumnus of Wharton School at the University of Pennsylvania graduated with an MBA and a doctorate degree. JeanMarie is knowledgeable in the areas of semi-empirical and quantum mechanical methods for molecular dynamics, X-ray and NMR refinement as well as protein structure prediction and drug design. She is also skilled in building and reconstructing companies.
JeanMarie Guenot’s entrepreneurship career started at Atlas Venture where she was in charge of venture capital investments and established life science companies. Her scientific career took off at Hoffman-La Roche, where she served as a principal scientist in Preclinical R&D. Hoffman-La Roche deals with the research and development of treatments for inflammation, metabolic diseases, oncology and autoimmune diseases. Before joining Amphivena Therapeutics, JeanMarie established and managed SKS Ocular. This ophthalmic company incubator specialized in dry AMD, therapeutics for macular degeneration, ocular inflammation, glaucoma, and technologies for the delivery of sustained release of ocular drugs.
CrunchBase shows that she also worked as a business advisor for Hoffman-La Roche. Guenot worked for PDL BioPharma as the vice president of Corporate & Business Development. While here, JeanMarie Guenot was responsible for mergers & acquisitions, licensing and alliance management for the company’s R&D and commercial product portfolios. She oversaw and negotiated the strategic collaboration of co-development and co-commercialization of the Biogen Idec-PDL 50:50, a transaction worth $800 million. It involved three candidates of phase 2 cancer and autoimmune disease drug.
In addition, Guenot LLC approved the ophthalmic indication for the oncology drug to Ophthotech Corporation. JeanMarie has a deep background in the management of portfolio, alliance and projects in fields of cardiovascular diseases, oncology, autoimmune diseases, ophthalmic diseases and neurology. This information was originally mentioned on Amphivena’s website as outlined in the following link http://amphivena.com/leadership/
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!